Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

Analysts already were skeptical about AbbVie's $5bn peak earnings projections for the ADC, but now some wonder if so-so data...

      

Related Stories

• Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs
• The Ups and Downs Of US Drug Pricing Policy
• Zealand Rushes Out Good Safety News On Phase III Dasiglucagon Rescue Pen

 

Original Article: Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions

More From BioPortfolio on "Weak Rova-T Data May Imperil AbbVie's Larger Cancer Ambitions"